-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OwSo9AdIinjTujXrYEHymwqfhPYvK7O4UP9KhxojvXKBnIC80r62uCGgyS8012uh IKlfjAjGucHTpc5h5ZoWiA== 0001005477-06-005930.txt : 20061215 0001005477-06-005930.hdr.sgml : 20061215 20061215113935 ACCESSION NUMBER: 0001005477-06-005930 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061213 FILED AS OF DATE: 20061215 DATE AS OF CHANGE: 20061215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000944522 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133671221 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4 SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 2034984210 MAIL ADDRESS: STREET 1: FOUR SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 FORMER COMPANY: FORMER CONFORMED NAME: ONCORX INC DATE OF NAME CHANGE: 19950615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHMEDLIN KAREN CENTRAL INDEX KEY: 0001140150 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26534 FILM NUMBER: 061279275 BUSINESS ADDRESS: STREET 1: VION PHARMACEUTICALS INC STREET 2: 4 SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 065111 BUSINESS PHONE: 2034984210X534 MAIL ADDRESS: STREET 1: VION PHARMACEUTICALS INC STREET 2: 4 SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 edgar123.xml FORM 4 X0202 4 2006-12-13 0 0000944522 VION PHARMACEUTICALS INC VION 0001140150 SCHMEDLIN KAREN VION PHARMACEUTICALS INC 4 SCIENCE PARK NEW HAVEN CT 06511 0 1 0 0 VP Finance and CAO Common Stock 2006-12-13 4 A 0 166666 0 A 260954 D Award of restricted shares of common stock under the Vion Pharmaceuticals, Inc. 2005 Stock Incentive Plan. Shares vest at the earliest of: (i) December 31, 2008; (ii) Change of Control; or (iii) approval of an NDA to market Cloretazine. Karen Schmedlin 2006-12-15 -----END PRIVACY-ENHANCED MESSAGE-----